Under the agreement DSM Pharmaceutical can use Codexis’ custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM’s InnoSyn route scouting services.
The DSM InnoSyn route scouting team provides value creating solutions to its customer by integrating enzyme technology with the range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors.
Codexis technology enables development of new manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste.
Codexis Pharmaceutical Services & Enzyme Products president Joseph Sarret said they are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale.